TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07563881: Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

Sponsor: Rapport Therapeutics Inc. · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 333 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$661,152

Rescue Site Savings

+$440,768

Unlock Full NCT07563881 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07563881 Rescue Dossier →